MEMPHIS, TN – In a groundbreaking study published today in The Lancet Oncology, scientists at St. Jude Children’s Research Hospital have unveiled a critical insight into the long-term health of childhood cancer survivors: their genetic makeup, alongside the life-saving treatments they received, significantly contributes to their risk of developing secondary cancers. This pioneering research not only confirms these associations but, for the first time, quantifies the proportional contributions of various factors at a population level, offering a more precise roadmap for preventing and managing the leading cause of mortality among these resilient individuals.
The study, leveraging the unparalleled datasets of the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS) – two of the world’s foremost childhood cancer survivor cohorts housed at St. Jude – marks a significant step forward in understanding the intricate interplay between inherited predispositions and therapeutic exposures. The findings are poised to revolutionize clinical guidelines, advocating for more personalized surveillance strategies that consider a survivor’s unique genetic profile in addition to their treatment history.
Main Facts: A New Lens on Survivor Health
The central revelation of the St. Jude study is the quantified contribution of both genetic predisposition and prior cancer treatment to the incidence of secondary cancers. Historically, the focus in survivorship care has predominantly been on the adverse effects of treatment, particularly radiation and chemotherapy. While these remain critical factors, this new research definitively places genetics as an equally, and in some cases, more potent contributor to subsequent cancer risk.
Dr. Yadav Sapkota, PhD, a corresponding author from St. Jude’s Department of Epidemiology and Cancer Control, articulated the study’s core finding: "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition. We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level."
This attribution is crucial. It moves beyond simply identifying risk factors to establishing their relative weight, providing clinicians with a more granular understanding of individual patient risk. The study determined that radiation exposure accounted for a substantial portion—approximately 40% or more—of secondary cancer risk. Chemotherapy’s contribution ranged from 8% to 35%, depending on the specific cancer type. However, perhaps the most striking finding was the significant, and previously underestimated, role of genetic predisposition, which, through polygenic risk scores (PRS), contributed 5% to 37% of the risk, often rivaling or exceeding the impact of chemotherapy for certain secondary cancers. In contrast, lifestyle factors, such as diet and exercise, showed a comparatively smaller contribution of 1% to 6% at the ages studied.
The implications are profound. With secondary cancers representing the primary cause of mortality for long-term childhood cancer survivors, a more comprehensive understanding of their etiology is not just beneficial, but essential. This research provides the evidentiary basis for a paradigm shift in how healthcare providers assess and manage the ongoing health of this vulnerable population.
The Journey to Understanding: A Chronology of Research
The narrative of childhood cancer survivorship has evolved dramatically over the past half-century. What began as a desperate struggle for survival has transformed into a sophisticated field dedicated to not only curing the disease but also ensuring a high quality of life for those who overcome it.
Early Insights and the Emergence of the Problem
In the mid-20th century, a diagnosis of childhood cancer was often a death sentence. The advent of aggressive chemotherapy and radiation therapies in the 1960s and 70s began to change this grim prognosis, leading to steadily improving survival rates. However, as more children survived into adulthood, a new set of challenges emerged: the long-term, often debilitating, side effects of their life-saving treatments. Among these, the development of secondary primary cancers – a new cancer unrelated to the original diagnosis – became a particularly pressing concern.
Early epidemiological studies began to identify correlations between specific treatments, such as high-dose radiation to certain body parts or particular chemotherapeutic agents, and an increased risk of subsequent malignancies. These initial observations, while critical, primarily focused on identifying individual risk factors in isolation. They highlighted the problem but lacked the comprehensive, population-level quantification needed to fully understand the intricate web of causality. The sheer complexity of distinguishing between treatment-induced effects and other potential contributors, including inherited predispositions, remained a significant hurdle.
The Genesis of Large Cohort Studies
Recognizing the urgent need for systematic, long-term follow-up of childhood cancer survivors, institutions like St. Jude Children’s Research Hospital spearheaded monumental research initiatives. This led to the establishment of two of the most significant cohorts in pediatric oncology:
- The Childhood Cancer Survivor Study (CCSS): Launched in 1994, the CCSS is a multi-institutional, retrospective cohort study that follows over 35,000 individuals diagnosed with cancer before age 21 at one of 31 participating institutions across the U.S. and Canada. It collects extensive data on their initial cancer diagnosis, treatment exposures, and long-term health outcomes, including the incidence of secondary cancers and other late effects.
- The St. Jude Lifetime Cohort Study (St. Jude LIFE): Initiated in 2007, St. Jude LIFE is a prospective, single-institution cohort that rigorously evaluates more than 6,000 adult survivors of childhood cancer treated at St. Jude. Participants undergo comprehensive clinical assessments, including detailed health histories, physical examinations, and biological sample collection (e.g., blood for genetic analysis), providing an exceptionally rich dataset for understanding health trajectories.
These cohorts are invaluable because they provide the necessary scale and depth of data to track health outcomes over decades, allowing researchers to observe the delayed effects of childhood treatments and investigate a multitude of contributing factors. They represent an unprecedented commitment to understanding the full scope of survivorship.
Evolving Methodologies: From Association to Attribution
Previous research within these cohorts has successfully established strong associations between various treatment exposures (e.g., radiation dose, specific chemotherapeutic agents), genetic susceptibilities (e.g., specific germline mutations), and lifestyle factors (e.g., smoking, obesity) with an increased risk of secondary cancers. However, a crucial knowledge gap persisted: the relative contribution of each factor at the population level. If radiation accounted for X% of the risk, chemotherapy for Y%, and genetics for Z%, what were these proportions, and how did they interact?
This latest St. Jude study directly addressed this gap. By combining the vast resources of the CCSS and St. Jude LIFE, researchers were able to move beyond mere association. Their sophisticated analytical framework allowed them to perform an attribution analysis, quantifying the precise proportion of secondary cancer risk that could be attributed to each category of factors. This methodological leap provides a much clearer picture of the primary drivers of secondary cancer development, laying the groundwork for more targeted and effective interventions.
Unpacking the Data: Supporting Evidence and Key Findings
The robustness of the study’s findings stems from its unparalleled dataset and rigorous methodology. By meticulously analyzing a wide array of information, the researchers were able to dissect the complex etiology of secondary cancers.
Methodology at a Glance
The St. Jude scientists meticulously compared data from over 10,000 survivors drawn from both the St. Jude LIFE and CCSS cohorts, collectively forming the largest survivor cohort in North America with extensive genetic sequencing information available for more than 12,000 individuals. This massive dataset encompassed:
- Detailed treatment exposures: Including specific chemotherapy agents, cumulative doses, and radiation fields and doses.
- Genetic information: Both common genetic variants, assessed through polygenic risk scores (PRS), and specific rare germline variants.
- Lifestyle factors: Such as diet, exercise, smoking status, and alcohol consumption.
- Comprehensive outcomes data: Specifically, the presence or absence of secondary cancers, meticulously documented over decades of follow-up.
This comprehensive approach allowed the researchers to disentangle the contributions of these various factors to the occurrence of secondary cancers, providing a powerful statistical framework for their attribution analysis. As co-author Dr. Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control, emphasized, "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing."
Radiation: The Enduring Legacy
The study reinforced the long-recognized and significant role of radiation exposure in driving secondary cancer risk. Quantifying its contribution at about 40% or more, the research highlights the enduring legacy of radiation as a potent carcinogen. Historically, radiation therapy was a cornerstone of many childhood cancer treatments, particularly for solid tumors and central nervous system malignancies. While incredibly effective at eradicating primary cancers, the collateral damage to surrounding healthy tissues often manifested years or even decades later as secondary cancers.
This finding provides strong support for the ongoing efforts in modern pediatric oncology to reduce radiation doses, limit radiation fields, and, where possible, replace radiation entirely with other effective modalities. The shift towards proton therapy, which allows for more precise targeting and reduced scatter radiation, and the development of highly effective chemotherapy regimens that can obviate the need for radiation in certain cancers, are examples of clinical practices already moving in this direction. The St. Jude study provides further empirical evidence validating these critical advancements in treatment protocols.
Chemotherapy and Genetics: A Complex Interplay
While radiation’s impact was relatively straightforward, the study revealed more nuanced and intricate relationships for chemotherapy and genetics. Chemotherapy’s contribution to subsequent cancer risk varied significantly by cancer type, ranging from 8% to 35%. The late effects of various chemotherapeutic agents, such as alkylating agents and topoisomerase inhibitors, have been well-described, including their potential to induce secondary leukemias and solid tumors.
However, the most compelling and surprising finding pertained to genetic predisposition. The contribution of inherited genetics to secondary cancer risk in survivors has been less well-recognized and certainly not quantified at this scale. To better understand this predisposition, researchers examined hundreds of common genetic variants previously associated with cancer development in the general population. These variants were aggregated into a "polygenic risk score" (PRS) – a statistical measure that reflects an individual’s cumulative genetic susceptibility to a particular disease. They also considered the impact of specific rare genetic variants known to confer high cancer risk.
The polygenic risk score approach revealed that, depending on the specific type of secondary cancer, genetics contributed a significant 5% to 37% of the total risk. This discovery challenges conventional wisdom, as Dr. Sapkota noted: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This revelation underscores that a survivor’s inherited predisposition is not merely a background factor but a powerful, quantifiable determinant of their long-term cancer risk.
Dr. Yutaka Yasui, PhD, also from St. Jude’s Department of Epidemiology and Cancer Control and a co-author, elaborated on the clinical utility of PRS: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This suggests that while PRS might not yet be universally applicable for broad population screening, their predictive power is significantly amplified within the high-risk context of childhood cancer survivors.
Lifestyle Factors: A Glimpse into the Future
In contrast to the strong influences of treatment and genetics, lifestyle factors such as diet and exercise appeared to contribute much less, accounting for only 1% to 6% of secondary cancer risk in this study. This finding, while initially surprising, comes with an important caveat. The survivors included in this analysis were primarily in their 20s and 30s. At these relatively young ages, the long-term cumulative effects of lifestyle choices on cancer development may not yet have fully manifested.
Dr. Sapkota prudently cautioned against misinterpreting this finding: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage – and patients to seek – a healthy lifestyle." This underscores that while lifestyle’s direct contribution to secondary cancer risk might become more apparent later in life, its overall importance for general health and other late effects in survivors remains undiminished.
Official Responses and Expert Commentary
The St. Jude research team’s commentary highlights not only the scientific achievement but also the profound implications for clinical practice and patient advocacy. Their collective insights underscore the study’s potential to reshape the landscape of survivorship care.
Voices from St. Jude
Dr. Yadav Sapkota, as the corresponding author, consistently articulated the significance of moving from association to attribution. His emphasis on the "population level" quantification underscores the generalizability and impact of the findings. His candid acknowledgment that the substantial role of genetics was "counter to conventional wisdom in the field" signals a necessary re-evaluation of long-held beliefs among clinicians and researchers alike. This willingness to challenge established paradigms is characteristic of high-impact scientific discovery. Dr. Sapkota’s concluding remarks encapsulate the ultimate goal: "Second cancers remain the leading cause of mortality for childhood cancer survivors. Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This vision of extended, healthier lives is the driving force behind St. Jude’s mission.
Dr. Greg Armstrong’s remarks reinforced the unique capabilities of the St. Jude LIFE and CCSS cohorts. His statement that "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts" is not merely an institutional boast but an accurate reflection of the immense resources, long-term commitment, and comprehensive data collection required to conduct such an ambitious and impactful study. The sheer volume of genetic sequencing data within these cohorts provides an unprecedented foundation for unraveling complex genetic influences.
Dr. Yutaka Yasui’s expert commentary on the clinical utility of polygenic risk scores is particularly insightful. He judiciously acknowledges the current limitations of PRS in the general population, where their predictive precision may not yet meet the threshold for routine clinical use. However, he then posits that "Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This distinction is critical. In a population already at elevated risk due to prior treatments, even a modest improvement in risk stratification provided by PRS can have significant clinical value, enabling more targeted and cost-effective surveillance.
Profound Implications for Future Care and Research
The findings from St. Jude are not merely academic; they carry profound practical implications for the clinical care of childhood cancer survivors and will undoubtedly shape the trajectory of future research in this vital field.
Personalized Risk Assessment
The most immediate and impactful implication is the move towards truly personalized risk assessment. Dr. Sapkota highlighted this, stating, "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk. Our study suggests that we need to better account for genetic predisposition in this population." This means that clinicians will increasingly need to consider a survivor’s genetic profile alongside their treatment history when developing long-term surveillance plans.
For individuals identified with a strong genetic predisposition to certain cancers, combined with specific treatment exposures, the current standard of care may need to be augmented. This could translate into more regular and intense cancer screenings, utilizing advanced imaging techniques or biomarker tests, to catch a second cancer at its earliest, most treatable stage. Conversely, those identified with a lower genetic risk might benefit from less intensive, yet still vigilant, surveillance protocols, optimizing healthcare resource allocation and reducing patient burden. This knowledge also empowers survivors to better understand their individual risk factors and actively advocate for appropriate screening and preventive measures with their healthcare providers.
Guiding Clinical Practice and Prevention Strategies
This research provides a powerful evidence base for updating clinical guidelines for survivorship care. Professional organizations like the Children’s Oncology Group (COG) develop comprehensive guidelines for the follow-up of childhood cancer survivors. The St. Jude study offers compelling data that can be directly integrated into these recommendations, ensuring that genetic screening and interpretation of polygenic risk scores become a standard component of risk assessment.
Furthermore, the quantified insights into the contributions of radiation and chemotherapy reinforce the ongoing imperative to develop less toxic cancer treatments. By understanding which treatments carry the highest risk for specific secondary cancers, researchers can prioritize the development of alternative therapies that maintain efficacy while minimizing long-term sequelae. This forward-looking approach to prevention at the point of initial treatment is crucial for improving the overall health trajectory of future generations of survivors.
Future Directions for Research
The St. Jude study opens numerous avenues for future research, promising to further refine our understanding and improve patient outcomes:
- Gene-Environment Interactions: While the study quantified independent contributions, future research will undoubtedly delve deeper into how specific genetic variants interact with particular treatment exposures to modify risk. Understanding these complex interactions could lead to even more precise risk prediction models.
- Refining Polygenic Risk Scores: Further development and validation of polygenic risk scores across diverse survivor populations are needed. This includes identifying additional common and rare genetic variants and exploring how PRS perform for a broader spectrum of secondary cancer types.
- Longitudinal Studies on Lifestyle Factors: As the current study’s participants age, it will be crucial to re-evaluate the contribution of lifestyle factors to secondary cancer risk. Long-term follow-up will reveal if their impact becomes more significant later in life, necessitating targeted lifestyle interventions.
- Development of Novel Therapeutic and Screening Strategies: Genetic insights could lead to the development of new targeted therapies for individuals with specific genetic predispositions or to novel non-invasive screening methods that leverage genetic markers for early detection.
In essence, this landmark research from St. Jude Children’s Research Hospital is a beacon of hope for childhood cancer survivors. By illuminating the complex interplay of genetics and treatment in the genesis of secondary cancers, it provides the essential knowledge base for transforming care, preventing disease, and ultimately extending the healthy, productive lives of those who have already triumphed over so much.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors are Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui; St. Jude; Qi Liu; University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia; University of Minnesota; Monica Gramatges, Baylor College of Medicine; Rebecca Howell, University of Texas MD Anderson Cancer Center and Smita Bhatia; University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
About the Author
